- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04102202
BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
March 22, 2021 updated by: Breath of Life International Pharma Ltd
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, Safety & Efficacy Trial of BOL-DP-o-05 as an Add-On Treatment for Preservation of Beta-Cell Function in Subjects With Newly-Diagnosed T1DM
BOL-DP-o-05 as an Add-On Treatment for Preservation of Beta-Cell Function in Subjects With Newly-Diagnosed Type 1 Diabetes Mellitus (T1DM)
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups study in which subjects will be randomized to receive either BOL-DP-o-05 or placebo as an Add-On Treatment.
The study evaluates the effect of BOL-DP-o-05 for Preservation of Beta-Cell Function in Subjects with Newly-Diagnosed Type 1 Diabetes Mellitus (T1DM).
The study includes a screening period up to three weeks followed by a 48-week treatment period
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 30 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent obtained before any trial-related activities.
- T1DM ≤ 20 weeks prior to screening.
- Male or female, aged 5-30 years old (both inclusive) at the time of signing the informed consent form.
- Non-fasting peak C-peptide ≥0.2 nmol/l during mixed-meal tolerance test (MMTT) at Visit 1.
- BMI ≥18.5 kg/m2.
- Presence of one or more islet-specific autoantibodies at the screening.
- Insulin dependence, unless in temporary spontaneous remission ("honeymoon period").
Exclusion Criteria:
- Daily insulin usage > 1 U/kg per day at screening
- History of recurrent (e.g. several times a year) of severe (e.g. pneumonia) or chronic infections or conditions predisposing to chronic infections.
- History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate documented therapy.
- Vaccination within 4 weeks before randomization.
- Receipt of any other concomitant medications or herbal products that can influence the immune system within 90 days prior to screening.
- History of pancreatitis (acute or chronic).
- Any past or current diagnosis of malignant neoplasms.
- Known impairment of the immune system, except for T1DM, coeliac disease, alopecia, autoimmune antibodies not considered clinical important (e.g. thyroid antibodies without any clinically important thyroid disease), and vitiligo.
- Patients with a psychiatric condition (e.g. severe anxiety, psychosis) that would interfere with the study as determined by the primary investigator.
- Patients with known allergy to one or more of the study drug components.
- Female patients who are pregnant, lactating, or who want to get pregnant during the study period. In the case of young patients, the PI should raise this point with the patient/family.
- Male subjects who want their partner to get pregnant.
- Female of child-bearing potential who do not agree to utilize medically acceptable and reliable means of birth control during the study and for 1 month following the last dose of the study unless the patient is young and the PI speaks with the patient/family and waived the criteria due to young age.
- Patients with a history of alcohol or any psychoactive substance abuse or dependence (including alcohol but excluding nicotine and caffeine).
- Patients with a first-degree family history of a psychiatric condition diagnosed at age<30 years.
- Patients with congestive heart failure or any other chronic disease.
- Patients with heart failure, psychotic state in the past, anxiety disorder, and heredity significant psychiatric inheritance in first-degree family relative, especially in patients younger than 30, and a history of addiction or drug abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Placebo
|
EXPERIMENTAL: BOL-DP-o-05
|
BOL-DP-o-05
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the effect of BOL-DP-o-05 on preservation of beta-cell function
Time Frame: up to week 48
|
Plasma levels of C-peptide concentration
|
up to week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of diabetic ketoacidosis episodes
Time Frame: Through study completion, an average of 48 weeks
|
Urine and plasma levels for ketones
|
Through study completion, an average of 48 weeks
|
Number of severe hypoglycaemic episodes
Time Frame: Through study completion, an average of 48 weeks
|
Plasma glucose level
|
Through study completion, an average of 48 weeks
|
Peak MMTT stimulated C-peptide concentration
Time Frame: Base line and week 48
|
Plasma levels of C-peptide concentration
|
Base line and week 48
|
To assess the change in fasting C-peptide
Time Frame: Baseline to week 24 and week 48
|
Plasma levels of C-peptide concentration
|
Baseline to week 24 and week 48
|
To assess the change in HbA1c
Time Frame: Baseline to weeks 24 and 48
|
HbA1c in plasma
|
Baseline to weeks 24 and 48
|
To evaluate total daily insulin dose
Time Frame: Week 24 and week 48
|
Insulin levels in units per kg
|
Week 24 and week 48
|
To Assess the percentage of patients that maintain stimulated peak C-peptide ≥ 0.2nmol/L
Time Frame: At week 48
|
Plasma levels of C-peptide
|
At week 48
|
To Assess the percentage of patients that achieve glycemic target of HbA1c ≤ 7.5%
Time Frame: At week 24 and week 48
|
HbA1c in plasma
|
At week 24 and week 48
|
To assess the percent of subjects who require a daily insulin dose < 0.5 IU/kg body weight
Time Frame: After 12 months of first treatment
|
Plasma glucose levels
|
After 12 months of first treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
November 15, 2020
Primary Completion (ANTICIPATED)
March 22, 2021
Study Completion (ACTUAL)
March 22, 2021
Study Registration Dates
First Submitted
September 15, 2019
First Submitted That Met QC Criteria
September 22, 2019
First Posted (ACTUAL)
September 25, 2019
Study Record Updates
Last Update Posted (ACTUAL)
March 24, 2021
Last Update Submitted That Met QC Criteria
March 22, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BOL-P-023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type1 Diabetes Mellitus
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedType1 Diabetes MellitusUnited States
-
Massachusetts General HospitalCompletedType1 Diabetes MellitusUnited States
-
Universidad Loyola AndaluciaUnknown
-
Jessa HospitalCompleted
-
Eli Lilly and CompanyCompletedA Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)Type1 Diabetes MellitusUnited States
-
AdociaCompleted
-
Second Xiangya Hospital of Central South UniversityRecruitingType1 Diabetes Mellitus | Autoimmune DiabetesChina
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Chinese University of Hong KongRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States